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Abstract: Antimicrobial resistance (AMR) has been identified by the World Health Organization
(WHO) as one of the ten major threats to global health. Advances in technology, including
whole-genome sequencing, have provided new insights into the origin and mechanisms of AMR.
However, our understanding of the short-term impact of antimicrobial pressure and resistance on
the physiology of bacterial populations is limited. We aimed to investigate morphological and
physiological responses of clinical isolates of E. coli under short-term exposure to key antimicrobials.
We performed whole-genome sequencing on twenty-seven E. coli isolates isolated from children
with sepsis to evaluate their AMR gene content. We assessed their antimicrobial susceptibility
profile and measured their growth dynamics and morphological characteristics under exposure
to varying concentrations of ciprofloxacin, ceftriaxone, tetracycline, gentamicin, and azithromycin.
AMR was common, with all organisms resistant to at least one antimicrobial; a total of 81.5%
were multi-drug-resistant (MDR). We observed an association between resistance profile and
morphological characteristics of the E. coli over a three-hour exposure to antimicrobials. Growth
dynamics experiments demonstrated that resistance to tetracycline promoted the growth of E. coli
under antimicrobial-free conditions, while resistance to the other antimicrobials incurred a fitness
cost. Notably, antimicrobial exposure heterogeneously suppressed bacterial growth, but sub-MIC
concentrations of azithromycin increased the maximum growth rate of the clinical isolates. Our results
outline complex interactions between organism and antimicrobials and raise clinical concerns
regarding exposure of sub-MIC concentrations of specific antimicrobials.
Keywords: Escherichia coli; azithromycin; tetracycline; growth rate; fitness cost; antimicrobial
resistance; resistome; morphology; physiology
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1. Introduction
Antimicrobial resistance (AMR) in bacterial pathogens is a well-recognized global health problem,
causing significant mortality and morbidity. In 2016, 58.6% of Escherichia coli (E. coli), 34.5%
of Klebsiella pneumoniae (K. pneumoniae), 33.9% Pseudomonas aeruginosa, 55.4% of Acinetobacter spp.,
and 19.8% of Staphylococcus aureus isolates in Europe were resistant to at least one antimicrobial [1].
The situation in low- and middle-income countries (LMICs), such as Vietnam, may be worse,
where approximately 50% of E. coli [2] and 91% of Shigella flexneri [3] isolates from clinical samples
were resistant to at least three antimicrobial classes (multi-drug-resistant (MDR)). According to WHO,
hospitalization costs for patients infected with drug-resistant bacteria are significantly higher than
that for patients infected with susceptible bacteria [4]. Indeed, it is estimated that resistant pathogens
may result in a total economic cost of USD 0.5 billion and USD 2.8 billion in Thailand and the US,
respectively [5]. The outlook is bleak, as the discovery and development of new antimicrobials have
declined dramatically [6]. Hence, there is an urgent need for novel approaches to comprehend how
AMR organisms emerge and spread and understand how antimicrobials impact on bacterial cells.
E. coli is a member of the Enterobacteriaceae and a component of the healthy human gut microbiota.
E. coli has been reported as the most prevalent pathogen associated with bacteraemia in Asia (43.8%) [2]
and urinary tract infections in Africa (41.9%) [7]. In South America, diarrheagenic E. coli was responsible
for 45.2% of diarrheal cases in children under five years [8]. Particularly, ETEC (enterotoxigenic E. coli)
is estimated to cause approximately 222 million diarrheal cases and 51,200 deaths globally in 2016 [9].
The high prevalence and burden of E. coli has made it one of the most important pathogens and one of
the best studied group of microorganisms in science. However, we have limited contemporary data on
the impact of antimicrobials on MDR E. coli associated with disease. A scenario may be all too familiar
in LMICs where empirical antimicrobials are administered to patients without any microbiological
diagnostics or antimicrobial susceptibility testing.
Although antimicrobial susceptibility testing is the gold standard approach to identify and
describe resistant bacteria, it provides no insight into the molecular and cellular response triggered
by antimicrobial exposure. There have been previous investigations into the molecular mechanisms
of AMR in specific bacteria [2] and their morphological [10–12] and physiological characteristics [13]
under antimicrobial treatments. However, there are few studies directly linking molecular mechanisms
of AMR with the morphology and physiology of antimicrobial-resistant organisms. Given the high
burden of resistant E. coli in LMICs, we designed a holistic investigation to provide an in-depth
understanding of AMR in bloodborne E. coli from both a cellular and molecular perspective using
microscopic techniques and whole-genome sequencing. Additionally, we studied the growth dynamics
of pathogenic E. coli to measure the physiological changes of E. coli with a diverse compendium of
AMR genes upon short-term exposure to different antimicrobial classes.
2. Results
2.1. Resistome and Morphology Associated with AMR
The 27 clinical E. coli isolates exhibited a high prevalence of AMR phenotypes, with all isolates
resistant to at least one antimicrobial (Table 1). Among those, 70.4%, 70.4%, 88.9%, 74.1%, and 64.0%
were resistant to ciprofloxacin, azithromycin, ceftriaxone, tetracycline, and gentamicin, respectively
(Table 1). Additionally, 22/27 (81.5%) isolates were resistant to at least three different classes of
antimicrobials and defined as MDR [14].
Antibiotics 2020, 9, 735 3 of 15
Table 1. Minimum inhibition concentrations (MICs) and antimicrobial resistance of ATCC 25922 and
27 clinical isolates used in this study.
Isolate
ID
Minimum Inhibition Concentrations (mg/L)
CIP 1 AZI 1 CRO 1 TE 1 CN 1
E3585 32 (R) 48 (R) 256 (R) 256 (R) 256 (R)
E3823 32 (R) 48 (R) 256 (R) 256 (R) 256 (R)
E4569 0.064 (S) 12 (S) 32 (R) 4 (S) 1 (S)
E6348 0.38 (S) 8 (S) 256 (R) 4 (S) 256 (R)
E8964 0.38 (S) 64 (R) 256 (R) 256 (R) 64 (R)
E9833 0.38 (S) 16 (S) 256 (R) 256 (R) 1 (S)
E10085 32 (R) 48 (R) 256 (R) 16 (R) 256 (R)
E10487 32 (R) 256 (R) 256 (R) 256 (R) 96 (R)
E10996 0.094 (S) 16 (S) 256 (R) 256 (R) 1 (S)
E11030 32 (R) 4 (S) 0.094 (S) 256 (R) 64 (R)
E12236 0.25 (R) 256 (R) 1.5 (I) 256 (R) 1 (S)
E12241 0.094 (S) 8 (S) 0.064 (S) 128 (R) 1 (S)
E12674 32 (R) 6 (S) 64 (R) 128 (R) 1.5 (S)
E14252 12 (R) 16 (S) 256 (R) 256 (R) 32 (R)
E14488 32 (R) 256 (R) 256 (R) 4 (S) 16 (R)
E15475 32 (R) 256 (R) 256 (R) 256 (R) 1 (S)
E15476 32 (R) 256 (R) 256 (R) 256 (R) 1.5 (S)
E15583 32 (R) 256 (R) 256 (R) 256 (R) 1 (S)
E1456 0.25 (S) 48 (R) 256 (R) 64 (R) 256 (R)
E1965 32 (R) 256 (R) 256 (R) 4 (S) 256 (R)
E2408 32 (R) 256 (R) 256 (R) 4 (S) 64 (R)
E2542 32 (R) 256 (R) 256 (R) 4 (S) 256 (R)
E4751 32 (R) 256 (R) 256 (R) 256 (R) 256 (R)
E5306 0.38 (S) 48 (R) 256 (R) 256 (R) 256 (R)
E5610 32 (R) 256 (R) 256 (R) 4 (S) 256 (R)
E5896 0.38 (S) 256 (R) 128 (R) 256 (R) 256 (R)
E6227 32 (R) 256 (R) 256 (R) 256 (R) 1.5 (S)
ATCC25922 0.094 (S) 4 (S) 0.125 (S) 4 (S) 1.5 (S)
Susceptible 8/27 (29.6%) 8/27 (29.6%) 2/27(7.4%) 7/27 (25.9%) 10/27 (37.0%)
Intermediate 0/27 (0.0%) 0/27 (0.0%) 1/27 (3.7%) 0/27 (0.0%) 0/27 (0.0%)
Resistant 19/27 (70.4%) 19/27 (70.4%) 24/27 (88.9%) 20/27 (74.1%) 17/27 (63.0%)
1 CIP: ciprofloxacin, AZI: azithromycin, CRO: ceftriaxone, TE: tetracycline, CN: gentamicin, S: susceptible,
I: intermediate, R: resistant.
To investigate the AMR gene profiles of the 28-isolate collection, WGS was performed on
the 27 clinical E. coli isolates and a whole-genome sequence of E. coli ATCC 25922 was obtained
from the NCBI database. The most prevalent sequence type (ST) was ST1193, which accounted
for 8/27 isolates (29.6%); the remainder fell into 11 different STs (Figure 1b). A resistome analysis
demonstrated that resistance to azithromycin and tetracycline was associated with the presence of
mphA and the tet gene variants (tetA/tetR or tetB), respectively. All isolates harboring aac(3)-IIa were
resistant to gentamicin. In contrast, the resistome data were insufficient for explaining ciprofloxacin
resistance, which is commonly attributed to mutations in the Quinolone resistance determining
region (QRDR) [15]. Eleven and eight of 27 clinical isolates, respectively, harbored blaCTX-M-1
and blaCTX-M-9, which, as extended-spectrum beta-lactamases, confer resistance to third-generation
cephalosporins. Ceftriaxone MICs were positively correlated with the number of acquired resistance
genes to beta-lactams in these isolates (i.e., the more bla resistance genes, the higher the MIC; ρ = 0.66,
p < 0.001). Moreover, three isolates (ST69 and ST410) carried blaNDM-1, which is responsible for
carbapenem resistance.
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Figure 1. Bacterial morphology associated with antimicrobial resistance (AMR) and resistome. (a) The 
morphological features of E. coli after 3 h of being treated with ciprofloxacin. Brightfield images of E. 
coli in different morphologies, including, from left to right, cell lysis, ellipsoid, rod-like shape, and 
elongation, were acquired with a Nikon Ni-E upright microscope and a 100× objective lens. 
Morphology of the reference strain is in rod-like shape in drug-free condition. (b) The phylogenetic 
structure of E. coli with corresponding susceptibility, AMR genes, and morphology. (Left) The 
unrooted phylogenetic tree constructed from core genomes of the 28 E. coli isolates. (Right) Sequence 
type (ST) of those isolates obtained by mapping the whole-genome reads to a database of seven 
housekeeping genes. (Middle) Five heatmap blocks, each of which demonstrates (first column) 
antimicrobial susceptibility, (second column) morphology under exposure to antimicrobials, and 
(remaining columns) the presence (black) and absence (gray) of resistance genes against quinolone 
(CIP: ciprofloxacin), macrolide (AZI: azithromycin), 𝛽-lactam (CRO: ceftriaxone), tetracycline (TE), 
and aminoglycoside (CN: gentamicin). NF: non-identified ST. 
Aiming to explore the impacts of AMR and AMR genes on morphological changes, the 28 E. coli 
isolates (27 clinical isolates and the reference strain ATCC 25922) were subjected to antimicrobial 
exposure for three hours at CLSI breakpoint concentrations [16] and examined by light microscopy. 
The microscopy images were qualitatively classified into four principal categories: lysis, ellipsoid, 
rod-like shape, and elongation (Figure 1a). Figure 1b demonstrates that E. coli cells responded to 
antimicrobial exposure with differential modifications in their morphology, with some showing an 
association with a particular AMR phenotype. Specifically, ceftriaxone-susceptible and -intermediate 
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association with a particular AMR phenotype. Specifically, ceftriaxone-susceptible and -intermediate
resistant isolates were elongated, while resistant isolates retained a rod-like shape when exposed to
ceftriaxone (Figure 1b). Similarly, the majority of E. coli that were resistant to azithromycin, tetracycline,
and gentamicin retained a rod morphology, while the majority of susceptible organisms were ellipsoid
when exposed to these antimicrobials (Figure 1b).
Upon exposed to azithromycin and tetracycline, morphological changes were more heterogeneous
and not consistent with the respective susceptibility profiles of the organisms. For example,
of eight tetracycline-resistant E. coli isolates, five were ellipsoid and three were rod-like shape.
Ciprofloxacin exposure induced the highest level of morphological heterogeneity, in which resistant
organisms were rod-like shape, elongated, or a rod–elongated mixture; ciprofloxacin-susceptible
organisms were ellipsoid, rod-shaped, or lysed when exposed to ciprofloxacin. We did not observe
any obvious association between AMR gene content and bacterial morphological changes under
exposure to antimicrobials (Figure 1b), with the exception of the aforementioned rod morphology
with mphA, aac(3)-IIa gene, and tet gene variants conferring resistance to azithromycin, gentamicin,
and tetracycline, respectively.
2.2. Assessing the Growth Dynamics of E. coli under Exposure to Antimicrobials
The 28 E. coli isolates were exposed to different concentrations (0 to 256 mg/L) of ciprofloxacin,
azithromycin, ceftriaxone, tetracycline, and gentamicin; growth curves were performed over 24 h.
One isolate was chosen to perform three technical replicates (Figure S1) and the pair-wise correlation
coefficients among three replicates were calculated. An average correlation coefficient of 0.89 was
determined. Additionally, each isolate was exposed to azithromycin and tetracycline with an additional
one–two biological replicates to confirm the observed effects of resistance on their growth dynamics.
More than 2500 growth curves from the 28 E. coli isolates in different antimicrobial exposure
conditions were generated, and Gompertz’s, Baranyi’s, and the three-phase linear models were fit to
the growth curves. Gompertz’s and Baranyi’s models fit with the lowest MSE (mean square error)
and MAE (mean absolute error), and the highest ρ (correlation coefficient) and R2 (correlation of
determination) (Figure S2). However, the performance of Gompertz’s model was superior to that of
Baranyi’s model, which indicates that Gompertz’s (with three parameters) was the most suitable model
for these data. Consequently, we employed Gompertz’s model to estimate the growth parameters of
each curve for further analysis.
The growth features were plotted separately for five experimental conditions, and against
different antimicrobial concentrations as relative to the isolate’s respective MIC (Figure 2).
Generally, antimicrobials suppressed the growth of E. coli, which could be observed as the inferred
A reduced gradually and the area under the curve (AUC) reduced rapidly with increasing drug
concentrations. Alternatively, increased antimicrobial concentrations induced a prolonged λ in all
cases. The µ against relative drug concentration was more heterogenous and largely dependent on
antimicrobial class. The µ of E. coli treated with ciprofloxacin and tetracycline declined inversely with
respect to an increase in the respective antimicrobial concentrations. However, when organisms were
exposed to ceftriaxone, the µ remained constant, with some organisms showing increased µ at higher
concentrations. Notably, under azithromycin exposure, the general trend of the 28 E. coli isolates was
that µ increased in lower concentrations of the macrolide and then decreased gradually at higher
drug concentrations. These data suggest that sub-inhibitory concentrations of azithromycin induce an
increased rate of E. coli replication.
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Figure 2. The dynamics of the growth features. From top to bottom, lag-phase period (𝜆), maximum 
growth rate (𝜇 ), maximum cell density (A), and area under the curve (AUC) corresponding to 
antimicrobial concentration relative to MICs of 28 E. coli isolates from clinical samples. From left to 
right, ciprofloxacin (CIP), azithromycin (AZI), ceftriaxone (CRO), tetracycline (TE), and gentamicin 
(CN). The horizontal axis is antimicrobial concentrations relative to MICs of each isolate. The vertical 
axis represents the values of growth features. Bold lines are loess smooth functions and thin lines are 
the growth features of each isolate. 
On further investigation, we also found that tetracycline-resistant isolates possess a fitness 
advantage over susceptible isolates in both antimicrobial-free conditions and at 0.5 × MIC (Figure 3). 
Specifically, at 0.5 × MICs of tetracycline, the 𝜇 (p < 0.0001), 𝐴 (p < 0.001), and AUC (p < 0.0001) of 
the tetracycline-resistant E. coli were all significantly higher than those of the susceptible organism 
(Figure 3). Without antimicrobial exposure, the AUC of tetracycline-resistant isolates was 
significantly higher than that of susceptible isolates (p < 0.05). Conversely, azithromycin-susceptible 
E. coli in drug-free conditions had a fitness advantage over azithromycin-resistant E. coli with 
significantly higher AUCs (p < 0.05) (Figure 3). 
Figure 2. The dynamics of the growth features. From top to bottom, lag-phase period (λ), maximum
growth rate (µ), maximum cell density (A), and area under the curve (AUC) corresponding to
antimicrobial concentration relative to MICs of 28 E. coli isolates from clinical samples. From left to
right, ciprofloxacin (CIP), azithromycin (AZI), ceftriaxone (CRO), tetracycline (TE), and gentamicin
(CN). The horizontal axis is antimicrobial concentrations relative to MICs of each isolate. The vertical
axis represents the values of growth features. Bold lines are loess smooth functions and thin lines are
the growth features of each isolate.
On further investigation, we also found that tetracycline-resistant isolates possess a fitness
advantage over susceptible isolates in both antimicrobial-free conditions and at 0.5 ×MIC (Figure 3).
Specifically, at 0.5 ×MICs of tetracycline, the µ (p < 0.0001), A (p < 0.001), and AUC (p < 0.0001) of
the tetracycline-resistant E. coli were all significantly higher than those of the susceptible organism
(Figure 3). Without antimicrobial exposure, the AUC of tetracycline-resistant isolates was significantly
higher than that of susceptible isolates (p < 0.05). Conversely, azithromycin-susceptible E. coli in
drug-free conditions had a fitness advantage over azithromycin-resistant E. coli with significantly
higher AUCs (p < 0.05) (Figure 3).
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Figure 3. A comparison between the growth features for susceptible isolates and those for resistant 
isolates. From top to bottom, maximum cell density (A), maximum growth rate (𝜇), lag-phase period 
(𝜆), and area under the curve (AUC) of resistant isolates (dark gray) and those of susceptible isolates 
(light gray) without antimicrobial (left) and at half MICs (right). *: p-value < 0.05, **: p-value < 0.01, 
***: p-value < 0.001, ****: p-value < 0.0001. 
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To further investigate the impact of azithromycin and tetracycline resistance on the growth 
dynamics of E. coli, we plotted the growth features of resistant and susceptible isolates at different 
relative concentrations of these antimicrobials. Figure 4 shows a comparison between trends of 
growth features (as inferred by Gompertz’s model) on data from three replicates of resistant and 
susceptible organisms grown in increasing concentrations of azithromycin and tetracycline. We 
found that the 𝜆  of the tetracycline-resistant organism was lower than that of the susceptible 
organisms, while the 𝜇 and AUC of organisms resistant to tetracycline were higher than those of 
susceptible organisms. Conversely, the azithromycin-resistant organisms exhibited a longer 𝜆 , a 
higher 𝐴, and a lower 𝜇 than the azithromycin-susceptible organisms. Additionally, we found that 
the 𝜇  of both azithromycin-resistant and -susceptible E. coli peaked at low antimicrobial 
concentrations relative to MIC, which was supported by both Gompertz’s, Baranyi’s, and the three-
phase linear models (Figure S3). These data suggest that sub-inhibitory concentrations of 
azithromycin actually accelerate the growth of both susceptible and resistant E. coli. 
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2.3. Effects of Azithromycin and Tetracycline Resistance on Growth Dynamics of E. coli
To further investigate the impact of azithromycin and tetracycline resistance on the growth
dynamics of E. coli, we plotted the growth features of resistant and susceptible isolates at different
relative concentrations of these antimicrobials. Figure 4 shows a comparison between trends of
growth features (as inferred by Gompertz’s model) on data from three replicates of resistant and
susceptible organisms grown in increasing concentrations of azithromycin and tetracycline. We found
that the λ of the tetracycline-resistant organism was lower than that of the susceptible organisms,
while the µ and AUC of organisms resistant to tetracycline were higher than those of susceptible
organisms. Conversely, the azithromycin-resistant organisms exhibited a longer λ, a higher A, and a
lower µ than the azithromycin-susceptible organisms. Additionally, we found that the µ of both
azithromycin-resistant and -susceptible E. coli peaked at low antimicrobial concentrations relative
to MIC, which was supported by both Gompertz’s, Baranyi’s, and the three-phase linear models
(Figure S3). These data suggest that sub-inhibitory concentrations of azithromycin actually accelerate
the growth of both susceptible and resistant E. coli.
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and blue (susceptible isolates) lines indicate loess smooth regression. Gray shading represents 95% 
confident intervals. 
2.4. Elevation of Growth Rate in ermB- E. coli at Sub-MIC Concentrations of Azithromycin 
All azithromycin-resistant E. coli isolates (n = 19) carried mphA; additionally, seven harbored 
ermB and one isolate harbored lnuF. In order to investigate the influence of ermB, which was prevalent 
among E. coli resistant to azithromycin, on the growth features of E. coli, we compared the growth 
features of the E. coli with the presence (ermB+) and absence (ermB-) of this gene. The 𝜇, 𝐴, and AUC 
decreased in both ermB+ and ermB- isolates, while 𝜆  was elevated with increased relative 
concentrations of azithromycin (Figure 5a). We found that ermB+ E. coli exhibited a higher 𝐴 and 
AUC, shorter 𝜆, and lower 𝜇 than those of ermB- E. coli. At low concentrations of azithromycin 
relative to MICs, 𝜇 in ermB- isolates increased rapidly (peaked at ~0.03× MIC) and then gradually 
decreased. The highest 𝜇 value from the ermB+ organisms was lower than that from ermB- organisms, 
which peaked at a greater relative concentration of azithromycin. We further found that at lower 
concentrations of azithromycin (absolute concentrations of 1 and 2 mg/L), the ermB- organisms 
exhibited significantly higher 𝜇 than that of ermB+ organisms (Figure 5b), which was in concordance 
with data generated with relative azithromycin concentrations. Lastly, we found that MICs of ermB+ 
isolates were significantly higher than those of ermB- isolates (p < 0.05) (Figure 5c). Our data show 
that MICs against azithromycin are associated with the accumulation of the macrolide resistance 
gene. 
Figure 4. A comparison between growth features of resistant and susceptible isolates under exposure
to azithromycin and tetracycline. The horizontal axis is antimicrobial concentrations relative to MICs.
The vertical axis is values of the four growth features, including lag time (λ), maximum growth rate
(µ), maximum cell density (A), and area under the curve (AUC). For each isolate, growth features
were plotted against relative concentrations of antimicrobials as thin lines. Bold red (resistant isolates)
and blue (susceptible isolates) lines indicate loess smooth regression. Gray shading represents 95%
confident intervals.
2.4. Elevation of Growth Rate in ermB- E. coli at Sub-MIC Concentrations of Azithromycin
All azithromycin-resistant E. coli isolates (n = 19) carried mphA; additionally, seven harbored
ermB and one isolate harbored lnuF. In order to investigate the influence of ermB, which was prevalent
a ong E. coli resistant to azithromycin, on the growth features of E. coli, we compared the growth
features of the E. coli with the presence (ermB+) and absence (ermB-) of this gene. The µ, A, and AUC
decreased in both ermB+ and ermB- isolates, while λwas elevated with increased relative concentrations
of azithromycin (Figure 5a). We found that ermB+ E. coli exhibited a higher A and AUC, shorter λ,
and lower µ than those of ermB- E. coli. At low concentrations of azithromycin relative to MICs, µ in
ermB- isolates increased rapidly (peaked at ~0.03×MIC) and then gradually decreased. The highest µ
value from the ermB+ organisms was lower than that from ermB- organisms, which peaked at a greater
relative concentration of azithromycin. We further found that at lower concentrations of azithromycin
(absolute concentrations of 1 and 2 mg/L), the ermB- organisms exhibited significantly higher µ than
that of ermB+ organisms (Figure 5b), which was in concordance with data generated with relative
azithromycin concentrations. Lastly, we found that MICs of ermB+ isolates were significantly higher
than those of ermB- isolates (p < 0.05) (Figure 5c). Our data show that MICs against azithromycin are
associated with the accumulation of the macrolide resistance gene.
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Figure 5. The impact of the ermB gene on growth dynamics of azithromycin-resistant E. coli. (a) 
Growth features of E. coli in the presence (blue thin lines) and absence (red thin lines) of ermB. Vertical 
axis is values of 𝜆: lag time, 𝜇: maximum growth rate, A: maximum cell density, and AUC: area 
under the curve. Horizontal axis is antimicrobial concentration relative to MICs. Bold red and blue 
lines are loess smooth regression. Gray shading is 95% confident intervals. (b) Maximum growth rate 
(𝜇) of ermB- E. coli (red boxes) compared to that of ermB+ E.coli (blue boxes). Horizontal axis is the 
absolute concentration of azithromycin (mg/L). (c) Comparison MICs of ermB+ and ermB- E. coli. *: p-
value < 0.05. 
3. Discussion 
This study systematically assessed the physiological and morphological responses of AMR E. 
coli to clinically relevant antimicrobials. Regarding morphology, we found a relationship between 
resistance to ceftriaxone and cell elongation, which has been previously reported [17–22] and also 
utilized to rapidly detect resistant isolates [10,11]. However, we found that the molecular basis of 
AMR was not associated with antimicrobial-induced morphological responses. This observation 
suggests that morphology-based rapid antimicrobial susceptibility testing may be performed without 
prior knowledge of resistance mechanisms, which is a drawback of nucleic acid-based and protein-
based methods. A limitation of morphology-based testing is the highly diverse dependence of 
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Figure 5. The impact of the ermB gene on growth dynamics of azithromycin-resistant E. coli. (a) Growth
features of E. coli in the presence (blue thin lines) and absence (red thin lines) of ermB. Vertical axis
is values of λ: lag time, µ: maximum growth rate, A: maximum cell density, and AUC: area under
the curve. Horizontal axis is antimicrobial concentration relative to MICs. Bold red and blue lines are
loess smooth regression. Gray shading is 95% confident intervals. (b) Maximum growth rate (µ) of
ermB- E. coli (red boxes) compared to that of ermB+ E.coli (blue boxes). Horizontal axis is the absolute
concentration of azithromycin (mg/L). (c) Comparison MICs of ermB+ and ermB- E. coli. *: p-value < 0.05.
3. Discussion
This study systematically assessed the physiological and morphological responses of AMR
E. coli to clinically relevant antimicrobials. Regarding morphology, we found a relationship between
resistance to ceftriaxone and cell elongation, which has been previously reported [17–22] and also
utilized to rapidly detect resistant isolates [10,11]. However, we found that the molecular basis of AMR
was not associated with antimicrobial-induced morphological responses. This observation suggests
that morphology-based rapid antimicrobial susceptibility testing may be performed without prior
knowledge of resistance mechanisms, which is a drawback of nucleic acid-based and protein-based
methods. A limitation of morphology-based testing is the highly diverse dependence of morphological
changes on the types of antimicrobial, even for antimicrobials belonging to the same family. Considering
the β-lactams as an example, meropenem induces a spindle morphology in E. coli, while moxalactam
induces filamentous cells [23]. Thus, for each antimicrobial, a prior imaging dataset of both resistant
and susceptible organisms is required to infer the susceptibility of newly isolated organisms. For other
antimicrobials used in this study, the morphology–resistance correlation was less consistent, which may
be addressed by additional time data provided by live-cell imaging, which may be required to build
highly accurate antimicrobial susceptibility tests [11,24]. The heterogenous responses to CIP, AZI,
TE, and CN might be explained by the highly diverse genetic background of the E. coli collection
comprising of 11 different STs. Our results showed antimicrobial-induced morphological changes
in both resistant and susceptible isolates, suggesting that bacterial cells respond to drug pressure
despite the resistance to antimicrobials. This is probably due to the residue, in the cytoplasm, of active
antimicrobials which is not yet extruded by efflux pumps (e.g., TetA and TetB) or inactivated by enzymes
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(e.g., β-lactamases). This could also be explained by the weak interaction between antimicrobials
(e.g., CIP) and modified target proteins (e.g., mutated GyrA).
Due to improved manufacturing technology, the price of tetracyclines has decreased dramatically,
to the extent where they are the cheapest antimicrobials available. This has made tetracycline the
second most widely used antimicrobial worldwide [25]. Although the usage of tetracyclines in human
health is becoming less common, they are still important antimicrobials disease prevention and growth
promotion in animals [26]. Our data demonstrated a high prevalence of tetracycline-resistant E. coli
via the tet gene, which is in accordance with previous studies [27]. By comparing growth features
of E. coli treated with tetracycline, we found that tetracycline-resistant isolates possessed a fitness
advantage over susceptible isolates. This fitness advantage in the absence of the antimicrobial may
explain the ubiquity of tet gene carriage in the gut microbiota of children and the sustained persistence
of tetracycline resistance [27]. Our observations concur with a pharmacodynamic model [28], in which
the fitness of resistant E. coli did not differ from susceptible E. coli in antimicrobial-free conditions.
However, a recent study using growth curve analysis found that tetracycline resistance may exert a
fitness cost of up to 10% on E. coli compared with a wild-type strain [29].
Azithromycin has been listed by WHO as one of the critically important antimicrobial reagents for
human medicine [30]. Moreover, WHO have been developing guidelines to prophylactically prescribe
azithromycin to infants and children to reduce child mortality [31], which might increase the resistance
against macrolide antimicrobials globally [32]. Therefore, the molecular mechanisms and prevalence
of azithromycin resistance have been studied extensively [3,31,33–35]. However, the influence of
azithromycin exposure on the physiology of bacteria is not well understood. Here, we observed
an accelerated µ of both resistant and susceptible isolates under exposure to low concentrations
of azithromycin, raising a concern about potential impacts of this antimicrobial on developing
new resistant mutants. These results suggest further investigations are required to evaluate the
potential benefits of presumptive antimicrobial treatments compared to the risk of AMR development.
We speculate that at sub-MIC concentration, azithromycin molecules inhibit protein synthesis by
binding to the P site on the 50S subunit of the bacterial ribosome [36], inducing up-regulation of
ribosome synthesis which is associated with higher µ [37,38]. With increased concentration of the
macrolide, more ribosomal molecules are bound by azithromycin, which leads to insufficient protein
synthesis and reduction in µ.
Notably, the trend of µ in azithromycin-resistant E. coli was lower than the trend in
azithromycin-susceptible isolates. This observation may be experimental evidence supporting a
mathematical model for ribosome-targeting antimicrobials, which showed that faster growth induces
greater drug susceptibility [39]. Moreover, amongst the azithromycin-resistant E. coli harboring the
mphA gene, the ermB+ isolates exhibited lower µ than that of ermB-. We hypothesize two feasible causal
pathways of how ermB influences µ: (1) the presence/absence of ermB directly impacts on the µ trend or
(2) the presence of ermB increases the MICs of E. coli and consequently changes the trend of µ against
the relative concentration of azithromycin. The lower µ in ermB+ may be due to reduced ribosome
synthesis as ermB allows constitutive methylations of 23S rRNA [40], which protects the complexes
from azithromycin binding and potentially interferes with ribosome assembly. This suggests that the
presence/absence of ermB is likely to have a direct impact on µ.
This study has limitations. First, using these approaches, we were unable to develop an algorithmic
tool to quantitatively measure morphological changes and to categorize cell shapes. Therefore, the cell
shape classification may be subjective. Second, the relationship between morphology, growth dynamics,
and cell viability was not investigated. Third, the correlation between the live cell counts, measured
CFUs, and OD values, representing the density of both live and dead cells, was not verified. Although
bacterial enumeration provides information on the actual growth rates of the cultured bacteria, we opted
to analyze the growth of E. coli by monitoring OD as it enables high-throughput experiments with
biological replications. Lastly, the 27 E. coli isolates possessed potential cross-interaction among AMR
genes and high diversity in genetic background, which we were not able to address.
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4. Materials and Methods
4.1. Organisms and Whole Genome Sequencing
Twenty-seven E. coli isolates were isolated from the blood samples of Vietnamese children
hospitalized with sepsis in a previous study [41], which was approved by the Oxford Tropical
Research Ethics Committee (OxTREC, reference number 35–16) and the Ethic Committee of Children’s
Hospital 1 (reference number 73/GCN/BVND1). E. coli ATCC 25922 was included as a control in all
analyses. Minimum inhibitory concentrations (MICs) against ciprofloxacin, azithromycin, ceftriaxone,
tetracycline, and gentamicin were determined for all isolates by E-test (bioMerieux, Ivry-sur-Seine,
France) and serial broth dilution. Whole-genome sequencing was performed on the 27 clinical isolates.
DNA was extracted and purified using the Wizard Kit (Promega, Madison, WI, USA); the Nextera
XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA) was used to fragment DNA with
adapter ligation. DNA sequencing was performed on a MiSeq platform, using MiSeq Reagent Kit V2
(Illumina, San Diego, CA, USA) to produce 250-bp paired-end reads. Sequencing data are available at
www.ebi.ac.uk/ena (accession numbers from ERR4342165 to ERR4342191).
4.2. Monitoring and Modeling Bacterial Growth
For growth dynamics experiments, two-fold serial broth dilutions were conducted in 96-well
U-bottom plates (Thermo Fisher Scientific, Waltham, MA, USA) to obtain differing concentrations
of antimicrobials (from 0 to 512 mg/L) in 100 µL cation-adjusted Mueller-Hilton (MH) broth (Oxoid,
Basingstoke, UK). The selected antimicrobials were ciprofloxacin, azithromycin, ceftriaxone, tetracycline,
and gentamicin (Sigma Aldrich and AK Scientific, MO, USA). For each of the 28 E. coli isolates, one colony
of overnight-incubated E. coli was inoculated into 5 mL Luria-Bertani (LB) broth (Basingstoke, UK) for
3 h at 37 ◦C with shaking to reach OD600 ~ 0.3. The bacterial suspension was diluted 1/1000 in MH
broth, and 100 µL of the diluted suspension was mixed into each well of the 96-well plates. The final
concentration of antimicrobials in each well varied from 0 to 256 mg/mL (two-fold intervals, i.e.,
0, 0.5, 1, 2, . . . , 256). OD600 was measured on the plates every 15 min for 24 h at 37 ◦C, with shaking
before each measurement, in a FLUOstar OPTIMA microplate reader (BMG Labtech, Ortenberg,
Germany). The output data for each condition were curated and modified Gompertz’s (1), Baranyi’s (2),
and three-phase linear (3) models [13] were fit to the data by minimizing the mean square error (MSE).





(λ− t) + 1
]}
(1)









N0 , t ≤ λ
N0 + µ(t− λ) , λ < t < ts
A , t ≥ ts
(3)
where N(t) is the cell density, measured in OD600, at timepoint t, N0 is the cell density at t = 0, A is the
maximum cell density, µ is the maximum growth rate (per hour), λ is the lag time (in hours), ts is the
time to reach stationary phase (in hours), and C(t) = t + 1µ ln
[
e−µt + e−µλ − e−µ(t+λ)
]
. Area under the
curve (AUC) was approximately estimated from the growth curves using the Reimann summation
method. We termed the A, µ, λ, and AUC as growth features of a growth curve.
4.3. Bright-Field Microscopy
In order to investigate the morphology of E. coli in response to antimicrobial exposure, isolates were
inoculated on a nutrient agar (NA) plate and incubated overnight at 37 ◦C. For each isolate, <10 colonies
were inoculated into saline buffer (0.85% NaCl) to reach OD600 ~ 0.6. Resistant isolates were diluted
1/20 to reduce cell density in a field of view under microscopic examination. The selected antimicrobial
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(ciprofloxacin, azithromycin, ceftriaxone, tetracycline, and gentamicin) of its corresponding CLSI
break-point concentration [16] (i.e., ceftriaxone at 4 µg/mL) was added to the bacterial suspension and
to the thin NA plate (8 mL). Then, 100 µL of bacterial suspension was inoculated onto NA plates and
incubated for 3 h at 37 ◦C. Subsequently, small pieces of agarose pad were excised from the NA plate,
placed onto microscope slides, and examined under a Nikon Ni-e upright microscope with a 100×
objective lens.
4.4. Data Analysis
Data analysis was performed in R (version 3.5.3) programming language [42]. To estimate the
parameters from the models, the “optim” function (the R Stats package) was used to constrainedly
minimize the MSE between the actual and predicted OD values. For each isolate, the growth features
were plotted against relative MICs using the “ggplot2” and “gridExtra” packages. Wilcoxon rank-sum
test on boxplots was carried out on the “ggpubr” package. Multilocus sequence typing (MLST) of
E. coli was inferred from the whole-genome sequencing data using the SRST2 pipeline [43] on the seven
housekeeping genes, including adk, fumC, gyrB, icd, mdh, purA, and recA. Resistome analysis with AMR
gene identification was performed on the SRST2 pipeline. De novo assembly of sequencing data was
performed using SPAdes [44], gene annotation was completed using Prokka [45], and the pan- and core
genomes were deduced using Roary [46] with a minimum 99% blastp identity. Finally, a phylogenetic
tree was constructed on RAxML [47] using the alignment of the core genome from Roary’s output and
was visualized using the “ggtree” package.
5. Conclusions
In conclusion, we exploited growth dynamics and bacterial morphology to study the impact
of AMR in clinical E. coli isolates. The morphological responses to ceftriaxone were consistently
associated with the resistance to the antimicrobial, while the responses to other antimicrobials were
more heterogeneous. In the absence of the drug, tetracycline resistance confers a fitness advantage
on E. coli, while the other antimicrobials exert a measurable fitness cost (lower AUC and µ) on these
bacteria. At low concentrations of azithromycin, µ was accelerated and azithromycin-susceptible
isolates possessed higher µ than resistant isolates. We additionally observed an impact of AMR
genes on the growth dynamics of bacteria, in which E. coli harboring the ermB gene exhibited
lower µ than ermB- E. coli. Our study raises a concern regarding the persistence of AMR and the
development of new resistance phenotypes under antimicrobial exposure, showing the need for a
better understanding of how morphological and physiological responses contribute to the AMR and
tolerance in bacterial pathogens.
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between performance of Gompertz’s, Baranyi’s and three-phase linear model. For each growth curve, the three
models were utilized to predict OD values at every timepoints from 0 to 24h. The actual and predicted values
were used to calculate the mean square error (MSE), mean absolute error (MAE), correlation coefficient (ρ),
and correlation of determination (R2). The lower MSE and MAE; higher ρ and R2, the better a model is. Figure S3.
Comparison between growth parameters estimated from Gompertz’s, Baranyi’s and three-phase linear model.
Parameters include lag-phase period (λ), maximum growth rate (µ), and maximum cell density (A). The horizontal
and vertical axes are relative concentration of antimicrobials and values of the growth parameters, respectively.
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